A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Principal Investigator
David Gershenson, MD
Status
Closed to Accrual
Date Opened To Accrual
February 27 2014
Date Closed to Accrual
April 10 2018
Disease Site
Gynecologic [GY]
Ovarian
Phase
II/III
Developmental Therapeutics
No
Primary Objective
To estimate the progression-free survival (PFS) hazard ratio of trametinib compared to that of “commercially available therapies” consisting of one of five commercially available agents in women with recurrent low-grade serous carcinoma of the ovary or peritoneum previously treated with platinum-based chemotherapy.
Patient Population
Progression-free survival (PFS) hazard ratio of trametinib compared to that of “commercially available therapies” consisting of one of five commercially available agents in women with recurrent low-grade serous carcinoma of the ovary or peritoneum previously treated with platinum-based chemotherapy.
Target Accrual
250
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.